𝔖 Bobbio Scriptorium
✦   LIBER   ✦

L.4 Progress and limitations in the evaluation of drug treatment for negative symptoms

✍ Scribed by H.-J. Möller

Book ID
118599645
Publisher
Elsevier Science
Year
1997
Tongue
English
Weight
190 KB
Volume
7
Category
Article
ISSN
0924-977X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Quetiapine versus olanzapine for the tre
Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia
✍ Pinkhas Sirota; Irit Pannet; Ady Koren; Eleonora Tchernichovsky 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

## Abstract Negative symptoms are considered the most debilitating and refractory aspect of schizophrenia, being associated with poor social, occupational and global outcomes. Conventional antipsychotics have limited efficacy against these symptoms and poor tolerability profiles. Atypical antipsych

Validation of a 4-item Negative Symptom
Validation of a 4-item Negative Symptom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in schizophrenia
✍ Larry Alphs; Robert Morlock; Cheryl Coon; Pilar Cazorla; Armin Szegedi; John Pan 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB

The 16-item Negative Symptom Assessment (NSA-16) scale is a validated tool for evaluating negative symptoms of schizophrenia. The psychometric properties and predictive power of a four-item version (NSA-4) were compared with the NSA-16. Baseline data from 561 patients with predominant negative sympt